Related Experiment Video

Updated: May 27, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Thierry Passeron, Jean-Philippe Lacour, Maryline Allegra

    Experimental Dermatology
    |November 19, 2011
    PubMed

    Insights

    Genotyping alone is insufficient for melanoma treatment selection. Signaling and chemosensitivity assays, alongside genetic analysis, can identify effective targeted therapies like sorafenib for advanced melanoma.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Current melanoma targeted therapy selection relies heavily on identifying specific gene mutations.
    • Advanced melanoma often requires exploring alternative treatment strategies beyond standard genetic profiling.

    Observation:

    • A patient with stage IV melanoma, negative for common mutations (BRAF, NRAS, cKIT), showed MAPK pathway activation.
    • In vitro signaling and chemosensitivity assays revealed a significant response to sorafenib, a MAPK/RAF inhibitor.

    Findings:

    • Despite absent BRAF/NRAS/cKIT mutations, the MAPK pathway was active, indicating potential for targeted inhibition.
    • Combined treatment with sorafenib and dacarbazine resulted in a 9-month partial response, including lesion necrosis.

    Implications:

    • Chemosensitivity assays and pathway signaling studies offer valuable adjuncts to genotyping for personalized melanoma treatment.
    • This approach may improve treatment selection for patients with advanced melanoma, even without common driver mutations.

    More Related Videos

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Mutagenicity and Carcinogenicity01:25

    Mutagenicity and Carcinogenicity

    Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...